(Q34582560)

3 August 2017

title

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study (English)

1 reference

3 August 2017

main subject

phase II clinical trial

0 references

0 references

1 reference

1

Maryam Fouladi

1 reference

3 August 2017

3

Susan M Blaney

1 reference

3 August 2017

2

Clinton F Stewart

1 reference

3 August 2017

9

Amar Gajjar

1 reference

3 August 2017

10

Larry E Kun

1 reference

3 August 2017

12

Richard J Gilbertson

1 reference

3 August 2017

4

Arzu Onar-Thomas

1 reference

3 August 2017

Paula Schaiquevich

5

1 reference

3 August 2017

Roger J Packer

6

1 reference

3 August 2017

Stewart Goldman

7

1 reference

3 August 2017

J Russell Geyer

8

1 reference

3 August 2017

James M Boyett

11

1 reference

3 August 2017

publication date

9 July 2013

1 reference

Journal of Neuro-Oncology

3 August 2017

published in

1 reference

3 August 2017

volume

114

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

173-179

1 reference

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

A clinicobiological model predicting survival in medulloblastoma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4246636

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

7 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1166-7

Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1166-7

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1166-7

Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-013-1166-7

10.1007/S11060-013-1166-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference